Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

The role of glutathione in cancer.

Balendiran GK, Dabur R, Fraser D.

Cell Biochem Funct. 2004 Nov-Dec;22(6):343-52. Review.

PMID:
15386533
2.
3.

Role of glutathione in cancer pathophysiology and therapeutic interventions.

Singh S, Khan AR, Gupta AK.

J Exp Ther Oncol. 2012;9(4):303-16. Review.

PMID:
22545423
4.

Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review.

Yang P, Ebbert JO, Sun Z, Weinshilboum RM.

J Clin Oncol. 2006 Apr 10;24(11):1761-9. Review.

PMID:
16603718
5.

Expression of gamma-glutamyltransferase in cancer cells and its significance in drug resistance.

Pompella A, De Tata V, Paolicchi A, Zunino F.

Biochem Pharmacol. 2006 Jan 12;71(3):231-8. Epub 2005 Nov 21. Review.

PMID:
16303117
6.

Glutathione and glutathione-dependent enzymes in cancer drug resistance.

McLellan LI, Wolf CR.

Drug Resist Updat. 1999 Jun;2(3):153-164.

PMID:
11504486
7.

Environmental and chemical carcinogenesis.

Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA.

Semin Cancer Biol. 2004 Dec;14(6):473-86. Review.

PMID:
15489140
8.

Glutathione analogues in cancer treatment.

Hamilton D, Batist G.

Curr Oncol Rep. 2004 Mar;6(2):116-22. Review.

PMID:
14751089
9.

6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer.

Filomeni G, Turella P, Dupuis ML, Forini O, Ciriolo MR, Cianfriglia M, Pezzola S, Federici G, Caccuri AM.

Mol Cancer Ther. 2008 Feb;7(2):371-9. doi: 10.1158/1535-7163.MCT-07-0487.

10.

Naturally occurring resistance of bone marrow mononuclear and metastatic cancer cells to anticancer agents.

Richard C, Yau J, Th'ng JP, Duivenvoorden WC.

Clin Exp Metastasis. 2006;23(5-6):249-58. Epub 2006 Nov 3.

PMID:
17086360
11.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
12.

Dietary flavonoids: effects on xenobiotic and carcinogen metabolism.

Moon YJ, Wang X, Morris ME.

Toxicol In Vitro. 2006 Mar;20(2):187-210. Epub 2005 Nov 11. Review.

PMID:
16289744
13.

Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations.

Meurette O, Lefeuvre-Orfila L, Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel MT.

Clin Cancer Res. 2005 Apr 15;11(8):3075-83.

15.

Molecular mechanisms of drug resistance.

Longley DB, Johnston PG.

J Pathol. 2005 Jan;205(2):275-92. Review.

PMID:
15641020
16.

The role of glutathione in aging and cancer.

Richie JP Jr.

Exp Gerontol. 1992 Sep-Dec;27(5-6):615-26. Review.

PMID:
1426093
17.

Physical activity and cancer prevention : pathways and targets for intervention.

Rogers CJ, Colbert LH, Greiner JW, Perkins SN, Hursting SD.

Sports Med. 2008;38(4):271-96. Review.

PMID:
18348589
18.

Tissue transglutaminase-mediated chemoresistance in cancer cells.

Verma A, Mehta K.

Drug Resist Updat. 2007 Aug-Oct;10(4-5):144-51. Epub 2007 Jul 27. Review.

PMID:
17662645
19.

Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer.

Coley HM.

Cancer Treat Rev. 2008 Jun;34(4):378-90. doi: 10.1016/j.ctrv.2008.01.007. Epub 2008 Mar 25. Review.

PMID:
18367336
20.

Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species.

Powolny AA, Singh SV.

Pharm Res. 2008 Sep;25(9):2171-80. doi: 10.1007/s11095-008-9533-3. Epub 2008 Jan 23.

PMID:
18213451

Supplemental Content

Support Center